DURHAM, N.C. and WEST VALLEY CITY, Utah – June 19, 2025 – dGenThera, Inc., a biotechnology company pioneering theranostic molecular pairs, and Nusano, a physics company transforming the production of radioisotopes, today announced the signing of a letter of intent to provide dGenThera with access to high‑purity astatine‑211 (At‑211), a best‑in‑class alpha‑emitting isotope for cancer therapy.
Nusano will supply dGenThera with At-211 in quantities sufficient to enable the company’s ongoing preclinical studies, first‑in‑human trials, and subsequent clinical development. The agreement supports dGenThera’s goal of rapidly advancing its proprietary pipeline of targeted alpha therapies (TATs).
Astatine‑211: a uniquely advantageous alpha emitter
Ad Statistics
Times Displayed: 5259
Times Visited: 17 Brand-New FDA-cleared Advanced Ultrasound Medical Device available for sale or lease to Wound Care Centers or any other Medical Facilities.The Arobella 1000D is designed for non-contact or debridement ultrasound wound healing therapy, or any other wounds
Astatine‑211 is increasingly recognized as the alpha emitter of choice for targeted radiotherapeutics. Its pure alpha emission results in high‑energy, short‑range cytotoxicity that selectively destroys cancer cells while minimizing damage to surrounding healthy tissue. Unlike the chelated metal alpha emitters actinium-225 (Ac-225) and lead-212 (Pb-212), At‑211 has no problematic daughter isotopes that can detach and release payloads into healthy tissue and its 7.2-hour half-life provides an ideal window for systemic delivery and tumor targeting. Moreover, compared to metal emitter chelates, small molecules with covalently-attached At-211 are much more amenable to crossing the blood-brain barrier and targeting both primary brain cancers and brain metastases. These attributes make At‑211 ideally suited for precision oncology applications—a strategic fit with dGenThera’s molecular designs.
“We believe that At‑211 will be the foundation of the next generation of targeted alpha therapies,” said Louis Metzger, Co-founder and CEO of dGenThera. “Its therapeutic profile is unmatched—combining precision, potency, and safety. By working with Nusano, we are securing the isotope quantities needed not only to advance our near‑term preclinical experiments and mid-term clinical trials, but to also plan ahead for commercialization. We are excited to work with Nusano, whose technology is helping unlock At‑211’s full potential for patients and building ‘targeted radiotherapy 2.0’.”
Complementary technologies driving clinical progress
Historically, the widespread use of At‑211 in oncology has been limited by insufficient production capacity. Nusano’s breakthrough accelerator technology removes that limitation, opening the door to high volume, reliable At-211 production.
